Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies
if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the
same subfield and year (this is the minimum needed to enter the top 1%, not the average
within it), or reaches the top citation threshold in at least one of its specific research
topics.
CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma
20024.0k citationsBertrand Coiffier, Josette Brière et al.profile →
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late)
cites ·
hero ref
This map shows the geographic impact of P Lederlin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by P Lederlin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites P Lederlin more than expected).
This network shows the impact of papers produced by P Lederlin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by P Lederlin. The network helps show where P Lederlin may publish in the future.
Co-authorship network of co-authors of P Lederlin
This figure shows the co-authorship network connecting the top 25 collaborators of P Lederlin.
A scholar is included among the top collaborators of P Lederlin based on the total number of
citations received by their joint publications. Widths of edges
represent the number of papers authors have co-authored together.
Node borders
signify the number of papers an author published with P Lederlin. P Lederlin is excluded from
the visualization to improve readability, since they are connected to all nodes in the network.
All Works
20 of 20 papers shown
1.
Gisselbrecht, Christian, Didier Decaudin, Nicolas Mounier, et al.. (2009). 90yttrium Ibritumomab Tiuxetan (zevalin) Combined With Beam (z-beam) Conditioning Regimen Plus Autologous Stem Cell Transplantation in Relapsed Or Refractory Follicular Lymphoma. a Gela Phase Ii Prospective Study. Digital Access to Libraries. 94. 418.1 indexed citations
Gebhard, F., G Leverger, Ross Pinkerton, et al.. (1998). High efficacy of recombinant urate oxidase in prevention of renal failure related to tumor lysis syndrome (TLS).. Blood. 92(10).9 indexed citations
8.
Bosly, André, et al.. (1997). Superiority of late over early intensification in relapsing/refractory aggressive non-Hodgkin's lymphoma: A randomized study from the GELA: LNH RP 93. British Journal of Haematology. 102(1). 148–148.7 indexed citations
9.
Bosly, André, Anne Sonet, Gilles Salles, et al.. (1997). Late intensification is superior to early intensification in relapsing/refractory aggressive non-Hodgkin's lymphoma. A randomized study from the GELA: LNH RP93.. Experimental Hematology. 25(8). 16–16.1 indexed citations
Tréchot, P., et al.. (1995). [Acute liver disease during treatment with pipobroman and allopurinol].. PubMed. 24(9). 460–460.1 indexed citations
14.
Lederlin, P, et al.. (1992). [Lymphoproliferative syndromes after cardiac transplantation and treatment with cyclosporine. Report of 4 cases].. PubMed. 143(3). 155–9.3 indexed citations
15.
Witz, Francis, D Olive, P Lederlin, et al.. (1987). Intérêt des hautes doses de cytosine-arabinoside dans le traitement des leucémies aiguës résistantes.. La Presse Médicale. 16(4). 159–162.1 indexed citations
16.
Witz, Francis, D Olive, P Lederlin, et al.. (1987). [High-dose Cytosine-arabinoside for the Treatment of Resistant Acute-leukemia]. La Presse Médicale. 16(4). 159–162.2 indexed citations
Netter, P., et al.. (1981). [Bone marrow hypoplasia an pancytopenia related to the administration of cimetidine. Description of a case].. PubMed. 36(2). 202–3.2 indexed citations
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive
bibliographic database. While OpenAlex provides broad and valuable coverage of the global
research landscape, it—like all bibliographic datasets—has inherent limitations. These include
incomplete records, variations in author disambiguation, differences in journal indexing, and
delays in data updates. As a result, some metrics and network relationships displayed in
Rankless may not fully capture the entirety of a scholar's output or impact.